Get started
Work

A Multicenter Analysis of Intermediate-Dose Cyclophosphamide Versus Plerixafor and Granulocyte Colony Stimulating Factor for PB Progenitor Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Chemotherapies

Year: 2013
Type: article
Abstract: Peripheral blood progenitor cell (PBPC) mobilization with intermediate-dose cyclophosphamide (3-4 gm/m2) (ID-CY) and G-CSF when compared to low-dose CY (1-2 gm/m2)-based strategies, has been shown to have a favorable risk/benefit profile in multiple myeloma (MM) patients (pts) receiving novel induction therapies. However the relative efficacy of ID-CY as compared to plerixafor (P) in PBPC mobilization in MM pts is not known. Herein we report outcomes of ID-CY/G-CSF mobilization compared to P/G-CSF mobilization in MM pts treated with novel inductionregimens.
DOI: 10.1016/j.bbmt.2012.11.176
Authors: Farrukh Tauseef Awan, Samith Kochuparambil, Michael Craig, Aaron Cumpston, Sonia Leadmon, David DeRemer, Kathy Watkins, Jeremy Pantin, Vamsi Kota, Anand Jillella, Mehdi Hamadani
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2312864680
FWCI:
Cites:
Cited by:
Related to: 10